Search
SOLACI Congress
HomeCONGRESS

CONGRESS

View Category
Pharmacology

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular...
Dr. Omar Tupayachi -
Learn More
Coronary disease

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in...
Dr. Omar Tupayachi -
Learn More
Coronary disease

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated...
Dr. Omar Tupayachi -
Learn More
Structural Heart Disease

OPTION Trial: Left Atrial Appendage Closure

Atrial fibrillation ablation is a valid strategy. However, reoccurrence is frequent in these cases, often with asymptomatic...
Dr. Carlos Fava -
Learn More
Mitral valve

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has...
Dr. Carlos Fava -
Learn More
Structural heart disease

TCT 2024 – EVOLVED trial: Early Intervention for Patients with Severe Asymptomatic Aortic Stenosis and Myocardial Fibrosis?

Treating symptomatic severe aortic stenosis (AS) with aortic valve replacement is currently considered a class I recommendation,...
Dr. Andrés Rodríguez -
Learn More
Structural heart disease

TCT 2024 – TAVR UNLOAD: Moderate Aortic Stenosis with Ventricular Function Deterioration

The prevalence of aortic stenosis (AS) is on the rise in developed countries, and the link between...
Dr. Carlos Fava -
Learn More
Structural heart disease

TCT 2024 – EVOLVED Trial: Severe Aortic Stenosis and Myocardial Fibrosis

Severe aortic stenosis is increasingly common, especially in developed countries, and the current treatment of choice is...
Dr. Carlos Fava -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

TAVR in Small Annuli: What Valve Should We Use?

Dr. Carlos Fava - 0
One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Dr. Andrés Rodríguez - 0
Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Dr. Omar Tupayachi - 0
Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

Institutional News

April 9 – How to Apply for the SOLACI Research Grant 2025? Virtual Zoom Event

solaci - 0
The Latin American Society of Interventional Cardiology invites you to a new virtual event hosted by the SOLACI Research Department, aimed at clarifying doubts,...

Watch our event on Evidence and Controversies of Renal Denervation in 2025

solaci - 0
You can now watch our event, held in collaboration with Medtronic, titled "Evidence and Controversies of Renal Denervation in 2025." The event featured international experts...

March 26 – SOLACI Webinar: Evidence and Controversies in Renal Denervation in 2025

solaci - 0
The Latin American Society of Interventional Cardiology invites you to a new virtual event supported by Medtronic. On this occasion, we will hold a 60-minute...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy